Related Experiment Video
Updated: Apr 18, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Mutational spectrum of adult T-ALL
Martin Neumann1, Sebastian Vosberg2,3, Cornelia Schlee1
1Charité, Universitätsmedizin Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany.
Abstract:
Novel target discovery is warranted to improve treatment in adult T-cell acute lymphoblastic leukemia (T-ALL) patients. We provide a comprehensive study on mutations to enhance the understanding of therapeutic targets and studied 81 adult T-ALL patients. NOTCH1 exhibitedthe highest mutation rate (53%). Mutation frequencies of FBXW7 (10%), WT1 (10%), JAK3 (12%), PHF6 (11%), and BCL11B (10%) were in line with previous reports. We identified recurrent alterations in transcription factors DNM2, and RELN, the WNT pathway associated cadherin FAT1, and in epigenetic regulators (MLL2, EZH2). Interestingly, we discovered novel recurrent mutations in the DNA repair complex member HERC1, in NOTCH2, and in the splicing factor ZRSR2. A frequently affected pathway was the JAK/STAT pathway (18%) and a significant proportion of T-ALL patients harboured mutations in epigenetic regulators (33%), both predominantly found in the unfavourable subgroup of early T-ALL. Importantly, adult T-ALL patients not only showed a highly heterogeneous mutational spectrum, but also variable subclonal allele frequencies implicated in therapy resistance and evolution of relapse. In conclusion, we provide novel insights in genetic alterations of signalling pathways (e.g. druggable by γ-secretase inhibitors, JAK inhibitors or EZH2 inhibitors), present in over 80% of all adult T-ALL patients, that could guide novel therapeutic approaches.
Insights
This study reveals frequent genetic mutations in adult T-cell acute lymphoblastic leukemia (T-ALL), identifying novel targets like HERC1 and ZRSR2. These findings offer new therapeutic strategies for T-ALL patients.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Adult T-cell acute lymphoblastic leukemia (T-ALL) requires novel therapeutic targets for improved patient outcomes.
- Understanding the genetic landscape of adult T-ALL is crucial for identifying actionable mutations.
Purpose of the Study:
- To conduct a comprehensive mutation profiling study in adult T-ALL patients.
- To identify novel recurrent mutations and affected pathways for potential therapeutic targeting.
Main Methods:
- Whole-exome sequencing or targeted gene sequencing of 81 adult T-ALL patient samples.
- Analysis of mutation frequencies, pathways, and subclonal architecture.
Main Results:
- NOTCH1 mutations were most frequent (53%). Recurrent mutations were identified in transcription factors (DNM2, RELN), WNT pathway (FAT1), epigenetic regulators (MLL2, EZH2), DNA repair (HERC1), NOTCH2, and splicing factors (ZRSR2).
- The JAK/STAT pathway (18%) and epigenetic regulators (33%) were frequently altered, particularly in early T-ALL.
- Adult T-ALL exhibits a heterogeneous mutational spectrum and subclonal diversity linked to therapy resistance and relapse.
Conclusions:
- Genetic alterations in signalling pathways, including those targetable by γ-secretase, JAK, or EZH2 inhibitors, are present in over 80% of adult T-ALL patients.
- These findings provide critical insights into the molecular basis of adult T-ALL and guide the development of novel therapeutic strategies.
Related Concept Videos
01:39Mutations
01:35Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
02:21Cancers Originate from Somatic Mutations in a Single Cell